MAPT and Alzheimer disease: It has been demonstrated that AF267B lowers the amount of amyloid in rabbits and lessens cognitive impairments, as well as lowers the tau and amyloid levels in triple-transgenic AD mice, and targets major AD hallmarks by activating protein kinase C and a disintegrin and metalloprotease 17 (ADAM17) via M1 mAChR.